Stock Report

All about this stock under one free report Last Updated: 17-May-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Mersana Therapeutics Inc. (MRSN)

Stock Card factsheet share-fund-plan-icon

$29.08

$0.00 (0.00%)

As on 06-Jan-2026 09:30EDT

Market cap

info icon

$145 Mln

Revenue (TTM)

info icon

$33 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

32

Div. Yield

info icon

0 %

Mersana Therapeutics (MRSN) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 29.08 High: 29.08

52 Week Range

Low: 5.21 High: 36.25

Liquidityliquidity Low

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -5.1 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    -2.2

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-14.1

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    4,998,750

9 Years Aggregate

CFO

$-576.62 Mln

EBITDA

$-789.01 Mln

Net Profit

$-797.11 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Mersana Therapeutics (MRSN)
0.5 4.7 251.2 -16.3 -39.6 -42.6 --
BSE Sensex*
-11.1 -2.1 -8.9 -7.5 6.6 9.1 11.4
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 06-Jan-2026  |  *As on 15-May-2026  |  #As on 26-Oct-2023
Company
2025
2024
2023
2022
2021
2020
2019
Mersana Therapeutics (MRSN)
-19.1 -38.1 -60.4 -5.8 -76.6 364.4 40.4
S&P Small-Cap 600
4.0 7.0 13.9 -17.4 25.3 9.6 20.9
BSE Sensex
9.1 8.1 18.7 4.4 22.0 15.8 14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Peers

View Details
Company
 Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Mersana Therapeutics (MRSN)
29.1 145.4 33.2 -70.1 -202.9 -- -- 32.0
Cidara Therapeutics (CDTX)
221.4 6,961.6 0.0 -184.7 -- -65.5 -- 16.5

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Mersana Therapeutics (MRSN)

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in...  Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. As of January 6, 2026, Mersana Therapeutics, Inc. operates as a subsidiary of Day One Biopharmaceuticals, Inc.  Read more

  • President, CEO & Director

    Dr. Martin H. Huber M.D.

  • President, CEO & Director

    Dr. Martin H. Huber M.D.

  • Headquarters

    Cambridge, MA

  • Website

    https://www.mersana.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Mersana Therapeutics (MRSN)

The share price of Mersana Therapeutics Inc (MRSN) is $29.08 (NASDAQ) as of 06-Jan-2026 09:30 EDT. Mersana Therapeutics Inc (MRSN) has given a return of -39.57% in the last 3 years.

Since, TTM earnings of Mersana Therapeutics Inc (MRSN) is negative, P/E ratio is not available.
The P/B ratio of Mersana Therapeutics Inc (MRSN) is 32.03 times as on 06-Jan-2026, a 613 premium to its peers’ median range of 4.49 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2024
-0.10
-0.74
2023
-0.07
0.30
2022
-0.12
0.26
2021
-0.11
0.15
2020
-0.83
0.32

The 52-week high and low of Mersana Therapeutics Inc (MRSN) are Rs 36.25 and Rs 5.21 as of 17-May-2026.

Mersana Therapeutics Inc (MRSN) has a market capitalisation of $ 145 Mln as on 06-Jan-2026. As per SEBI classification, it is a Small Cap company.

Before investing in Mersana Therapeutics Inc (MRSN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.